logo.jpg
Fenix Marine Services Demonstrates Its Commitment To Corporate Social Responsibility
28 avr. 2021 16h24 HE | Fenix Marine Services
LOS ANGELES, April 28, 2021 (GLOBE NEWSWIRE) -- Fenix Marine Services released its Corporate Social Responsibility Annual Report 2020 which documents Fenix’s accomplishments over the past year....
logo.jpg
Fenix Marine Services Achieves Carbon Neutral Electricity Through Renewable Energy Credits
25 janv. 2021 10h48 HE | Fenix Marine Services
LOS ANGELES, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Fenix Marine Services LTD (“Fenix” or “FMS”), one of the largest terminal facilities at the Port of Los Angeles, today announced that it has used...
TrackX.png
TrackX and Topl Announce Strategic Partnership Combining Blockchain with Asset Management to Empower End-to-End Supply Chain Transparency
03 déc. 2020 08h00 HE | TrackX Holdings Inc.
Global IOT-enabled asset management and supply chain solutions company partners with ESG technology startup to deliver supply chain transparencyIntegrated solution will combine Topl’s purpose-built...
Equillium_Square_Logo.png
Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial
29 oct. 2020 16h13 HE | Equillium
Equillium plans to initiate global Phase 3 COVID-19 trial – EQUINOX – during Q4 2020 FDA indicates study could support BLA filing LA JOLLA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Equillium,...
logo.jpg
Fenix Marine Services Re-Affirms its Commitment to Corporate Social Responsibility
28 oct. 2020 19h42 HE | Fenix Marine Services
LOS ANGELES, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Fenix Marine Services (“FMS”), one of the largest container terminals in San Pedro Bay, has published today its Corporate Social Responsibility (CSR)...
Equillium_Square_Logo.png
Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients
15 sept. 2020 08h07 HE | Equillium
Equillium anticipates filing a U.S. IND for Itolizumab for COVID-19 and initiating a global Phase 3 clinical study in Q4 2020 LA JOLLA, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc....
lyra logo.jpg
Lyra Therapeutics Presents Clinical Data Demonstrating LYR-210’s Local Anti Inflammatory Effects for the Treatment of Chronic Rhinosinusitis
10 sept. 2020 18h00 HE | Lyra Therapeutics
Two additional presentations highlight supporting data for LYR-210’s clinical program covering key clinical endpoints for CRS and Lyra’s XTreo™ drug release performance Findings presented at the...
lyra logo.jpg
Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis
03 sept. 2020 16h05 HE | Lyra Therapeutics
WATERTOWN, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel...
lyra logo.jpg
Lyra Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
05 août 2020 16h05 HE | Lyra Therapeutics
- On track to report topline Phase 2 results for LYR-210 in chronic rhinosinusitis in 4Q 2020 - - Conference call and webcast today at 4:30 p.m. ET - WATERTOWN, Mass., Aug. 05, 2020 (GLOBE...
lyra logo.jpg
Lyra Therapeutics to Present at the BTIG Virtual Biotechnology Conference
04 août 2020 16h05 HE | Lyra Therapeutics
WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...